Martin Shkreli (C), chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York December 17, 2015. REUTERS/Lucas Jackson
Tom Fernandez and Marek Biestek resigned from KaloBios' board of directors, according to an 8-K filed Monday December 27 with the Securities and Exchange Commission.
It's the latest in a wave of departures of top execs from the company, which is set to de-list from the Nasdaq.
It has been a turbulent December for the San Francisco-based biopharmaceutical company, which saw its stock soar in November after Shkreli bought a majority stake in the company, only to see stock plummet after his arrest.
After falling by more than 50% in the wake of Shkreli's arrest, KaloBios shares were down another 5% at the open Monday December 27.